News NovoCure Limited

Stocks

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-12 pm EDT			5-day change	1st Jan Change
17.78 ^USD	+0.40%		+3.61%	+37.51%

Jun. 05	Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing	MT
Jun. 05	NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026	CI

All News

Mentions Relevance

Jun. 05	Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing	MT
Jun. 05	NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026	CI
Apr. 30	NovoCure Limited, Q1 2026 Earnings Call, Apr 30, 2026
Apr. 30	NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	NovoCure Shares Rise Following Q1 Financial Results	MT
Apr. 30	(NVCR) NovoCure Expects Full Year 2026 Revenue Range $690M - $710M, vs. FactSet Est of $694.7M	MT
Apr. 30	Earnings Flash (NVCR) NovoCure Posts Q1 Net Loss $0.62 a Share, vs. FactSet Est of $0.51 Loss	MT
Apr. 30	Earnings Flash (NVCR) Novocure Limited Reports Q1 Revenue $174.1M, vs. FactSet Est of $167.8M	MT
Apr. 30	NovoCure: Q1 Earnings Snapshot	AQ
Apr. 30	Novocure Reports First Quarter 2026 Financial Results	BU
Apr. 30	NovoCure Limited Updates Earnings Guidance for the Full Year 2026	CI
Apr. 21	NovoCure : Financial Reports 2026 novocure corporate responsibility report	PU
Apr. 01	Novocure to Report First Quarter 2026 Financial Results	BU
Mar. 26	NovoCure Says Phase 2 Trial of TTFields With Atezolizumab Meets Primary Endpoint in Pancreatic Cancer	MT
Mar. 26	Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer	BU
Mar. 26	Novocure Announces Positive Topline Results From Phase 2 PANOVA-4 Clinical Trial Of Tumor Treating Fields Therapy For Metastatic Pancreatic Cancer	CI
Mar. 02	Novocure Announces Optune Lua®? Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer	CI
Mar. 02	Novocure to Participate in 2026 Leerink Global Healthcare Conference	AQ
Mar. 02	Novocure Says It Receives Japan Reimbursement Approval For Optune Lua	MT
Mar. 02	Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer	BU
Feb. 27	Novocure to Participate in 2026 Leerink Global Healthcare Conference	BU
Feb. 26	NovoCure Limited, Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	NovoCure's Q4 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Issued	MT
Feb. 26	NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Earnings Flash (NVCR) Novocure Reports Q4 Loss $0.22 a Share, vs. FactSet Est of $0.41 Loss	MT